Novel Gene Expression Test, PROLARIS(TM), Accurately Predicts Prostate Cancer Recurrence 3/8/10
Data From Study of Myriad Genetics' Newest Diagnostic Test Presented at Genitourinary Cancers Symposium
Myriad Genetics, Inc. said data that provides further clinical validation supporting its newest molecular diagnostic product, PROLARIS(TM), was recently presented at the 2010 Genitourinary Cancers Symposium in San Francisco.
The study examined a well-described cohort of patients for which 10-year follow-up data were available following prostatectomy surgery. The study was carried out by Dr. Swanson and colleagues at the Scott and White Clinic, Temple, Texas and demonstrated that the PROLARIS molecular diagnostic test is a significant predictor of prostate cancer recurrence in training (p=0.01) and validation cohorts (p=0.00000006). In patients with Gleason scores (the most widespread method of prostate cancer tissue grading) below 7, PSA levels (protein produced by cells of the prostate gland) of less than 30ng/ml and with disease confined to the prostate, the PROLARIS test accurately identified those patients who had a low risk of disease recurrence with 95% certainty. In contrast, patients with a high-risk signature had a recurrence risk more than 4-fold higher than those with a low-risk signature. In the validation cohort, PROLARIS was also prognostic in patients with Gleason scores above 6, PSA levels of greater than 30ng/ml and with evidence of disease outside the prostate (p=0.0026)....
To view the complete article, please login or subscribe if you don't already have an account.